Anzeige
Mehr »
Samstag, 21.06.2025 - Börsentäglich über 12.000 News
+435 % Beteiligungsrendite durch TAO nach £5 Mio. Finanzierung und Bitcoin-Treasury-Strategie!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 890952 | ISIN: AU000000CSL8 | Ticker-Symbol: CSJ
Tradegate
19.06.25 | 08:00
135,40 Euro
+0,76 % +1,02
Branche
Biotechnologie
Aktienmarkt
S&P/ASX 50
1-Jahres-Chart
CSL LIMITED Chart 1 Jahr
5-Tage-Chart
CSL LIMITED 5-Tage-Chart
RealtimeGeldBriefZeit
133,02135,7220.06.
133,82135,1820.06.

Aktuelle News zur CSL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
CSL Aktie jetzt für 0€ handeln
DoFDA approves CSL's Andembry to prevent hereditary angioedema attacks3
DiWith FDA nod for HAE drug Andembry, CSL set to compete with Takeda's Takhzyro5
DiFDA clears CSL's swelling disease drug; Regeneron loses 23andMe auction6
DiFDA green lights CSL's once-monthly HAE drug Andembry-
DiLunch Wrap: Trump's Tehran warning jolts oil stocks, CSL climbs on FDA nod5
DiHot Stocks: 4DMedical, CSL, Emeco2
DiCSL shares push higher on US FDA approval14
13.06.When will CBA shares stop rising? CSL might give us a clue7
10.06.Buying CSL shares? Meet your new board director8
23.05.NICE endorses CSL Vifor's sparsentan for IgA nephropathy in adults19
23.05.NICE relents and backs drug for IgAN from CSL Vifor6
23.05.Vifor International AG (CSL Vifor): England's NICE recommends FILSPARI (sparsentan) as a treatment option for IgA nephropathy368First non-immunosuppressive dual-action therapy recommended by NICE for eligible patients with IgA nephropathy, a leading cause of kidney failure 1-3 NICE's recommendation is based on...
► Artikel lesen
22.05.Should I buy the dip on CSL shares?6
21.05.CSL Behring's first commercial shows Hizentra erasing germ concerns for primary immunodeficiency patients27
21.05.CSL shares among most expensive on ASX. Is now a good time to buy?3
12.05.Are CSL shares at risk from the Trump tariffs?19
11.05.What did CSL have to say at Macquarie's 2025 conference?3
05.05.CSL shares have climbed 10% since 11 April. Is it too late to buy?6
29.04.Travere Therapeutics, Inc.: Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI (sparsentan) for IgA Nephropathy373European Commission converts conditional approval of FILSPARI into standard marketing authorization for the treatment of IgAN EU approval is based on the complete data set from the Phase 3 PROTECT...
► Artikel lesen
29.04.Vifor International AG (CSL Vifor): CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI in IgA Nephropathy356European Commission converts conditional approval of FILSPARI (sparsentan) into standard marketing authorization for the treatment of IgA Nephropathy (IgAN) Decision follows positive...
► Artikel lesen
Weiter >>
89 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1